Skip to content

Startup & venture capital news

Estuary Biotherapeutics launches with USD 93m Series A

RA Capital leads financing for targeted kidney gene therapies

By /

LinkedInX
Estuary Biotherapeutics: Estuary Biotherapeutics launches with USD 93m Series A
Estuary Biotherapeutics. Licence: Not stated.

Estuary Biotherapeutics launched on 16 October 2026 with a USD 93 million Series A led by RA Capital Management. Together with an earlier USD 10 million seed round, the company disclosed USD 103 million in committed financing. Estuary is developing locally delivered gene therapies for autosomal dominant polycystic kidney disease. Its two lead programmes target the PKD1 and PKD2 genetic subtypes, with funding intended to support clinical proof of concept and further platform development. The founding team includes CEO Wayne Sackett, Yale researchers Stefan Somlo and Michael Caplan, and gene therapy specialist Xavier Anguela. Clinical efficacy remains to be established.

Keep reading

More Funding

All stories